Sobi and Hellenic Institute for the Study of Sepsis: anakinra improved overall clinical outcomes by 64% in hospitalised patients with COVID-19 pneumonia
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and the Hellenic Institute for the Study of Sepsis today announced positive top line results from the Investigator-sponsored SAVE-MORE study, which assessed the effect of anakinra in moderate to severe COVID-19 pneumonia patients. Early and targeted use of anakinra in addition to current standard of care in hospitalised patients with poor prognosis prevented either death or progression to severe respiratory failure, whilst increasing the number of patients who were discharged from hospital with no evidence of COVID-19 infection. SAVE-